Capricor Therapeutics(CAPR) - 2022 Q4 - Annual Report

groups once patients began treatment in the OLE. CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study. ● Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precisionengineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently presented new preclinical data o ...